AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2209411 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine (8 mg) daily for 18 days, then daily or alternate days from day 19-36
Number of subjects: 18
Study 889372 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin and erythromycin base
Number of subjects: 116
Study 889372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 31067546 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium bicarbonate supplementation to achieve serum HCO3- levels of 24 ± 1 mmol/L
Number of subjects: 35
Study 31067546 — intervention group
Group type: COMPARATOR
Intervention: Rescue group with serum HCO3- levels of 20 ± 1 mmol/L
Number of subjects: 35
Study 31067546 — intervention group
Group type: EXPERIMENTAL
Intervention: Change of serum phosphate
Number of subjects: 35
Study 28415988 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 0.2 mg/kg in 2-12 months age group
Number of subjects: 640
Study 28415988 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 0.2 mg/kg in 3-6 years age group
Number of subjects: 640
Study 28415988 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium (various dosages)
Number of subjects: 640
Study 26480545 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with motor imagery
Number of subjects: 62
Study 26480545 — intervention group
Group type: COMPARATOR
Intervention: Conventional western medication and passive movement
Number of subjects: 62
Study 23746749 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental material (test)
Number of subjects: 47
Study 23746749 — intervention group
Group type: COMPARATOR
Intervention: Control material (DCL)
Number of subjects: 47
Study 23746749 — intervention group
Group type: EXPERIMENTAL
Intervention: Both test and control materials
Number of subjects: 47
Study 23746749 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary teeth
Number of subjects: 47
Study 23746749 — intervention group
Group type: EXPERIMENTAL
Intervention: First molar teeth
Number of subjects: 47
Study 23746749 — intervention group
Group type: EXPERIMENTAL
Intervention: Supporting cusps
Number of subjects: 47
Study 23746749 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dentures supported by implants
Number of subjects: 47
Study 23746749 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective wear assessment
Number of subjects: 47
Study 21193975 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine first
Number of subjects: 76
Study 21193975 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis‐B vaccine first
Number of subjects: 76
Study 19020904 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based physiotherapy with a behavioural approach
Number of subjects: 59
Study 19020904 — intervention group
Group type: COMPARATOR
Intervention: Home-based training
Number of subjects: 59
Study 16840383 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg/d prednisone for 14 days
Number of subjects: 24
Study 16840383 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 24
Study 12617264 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-interferon alone
Number of subjects: 55
Study 12617264 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-interferon combined with prednisone
Number of subjects: 55
Study 12617264 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 55
Study 11783309 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheum palmatum (RP) and captopril
Number of subjects: 0
Study 11783309 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 0
Study 9375818 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse oral calcitriol
Number of subjects: 20
Study 9375818 — intervention group
Group type: COMPARATOR
Intervention: Intravenous calcitriol
Number of subjects: 20
Study 9375818 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 20
Study 1525793 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin
Number of subjects: 20
Study 1525793 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 20
Study 3908009 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (single-dose preoperative)
Number of subjects: 90
Study 3908009 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 90
Study 31027699 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus docetaxel
Number of subjects: 78
Study 31027699 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 78
Study 31027699 — intervention group
Group type: EXPERIMENTAL
Intervention: Low symptom burden (LSB)
Number of subjects: 78
Study 27927602 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system blockade
Number of subjects: 9340
Study 27927602 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan
Number of subjects: 9340
Study 27927602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9340
Study 27131642 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib 100 mg
Number of subjects: 68
Study 27131642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 25133963 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib 30 mg (qd)
Number of subjects: 239
Study 25133963 — intervention group
Group type: COMPARATOR
Intervention: celecoxib 200 mg (qd)
Number of subjects: 239
Study 22394170 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day of EPA-DHA (n = 453)
Number of subjects: 1850
Study 22394170 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/day of ALA (n = 467)
Number of subjects: 1850
Study 22394170 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA-DHA plus ALA (n = 458)
Number of subjects: 1850
Study 22394170 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 472)
Number of subjects: 1850
Study 19236730 — intervention group
Group type: EXPERIMENTAL
Intervention: BDNF rs7124442 TT genotype
Number of subjects: 268
Study 19236730 — intervention group
Group type: EXPERIMENTAL
Intervention: BDNF rs7103411 TT genotype
Number of subjects: 268
Study 19236730 — intervention group
Group type: EXPERIMENTAL
Intervention: BDNF rs6265 GG genotype
Number of subjects: 268
Study 17344513 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg/d for 14 days)
Number of subjects: 1074
Study 17344513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1074
Study 16266300 — intervention group
Group type: EXPERIMENTAL
Intervention: End-point rectal rewarming temperature at 35.5 degrees C (Group 1)
Number of subjects: 50
Study 16266300 — intervention group
Group type: COMPARATOR
Intervention: End-point rectal rewarming temperature at 37.0 degrees C (Group 2)
Number of subjects: 50
Study 11867825 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Number of subjects: 44
Study 11867825 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 44
Study 10195545 — intervention group
Group type: EXPERIMENTAL
Intervention: Size 4 LMA
Number of subjects: 50
Study 10195545 — intervention group
Group type: EXPERIMENTAL
Intervention: Size 4 FLMA
Number of subjects: 50
Study 10195545 — intervention group
Group type: EXPERIMENTAL
Intervention: Size 5 LMA
Number of subjects: 50
Study 10195545 — intervention group
Group type: EXPERIMENTAL
Intervention: Size 5 FLMA
Number of subjects: 50
Study 10195545 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 10195545 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA groups combined
Number of subjects: 50
Study 10195545 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA groups
Number of subjects: 50
Study 10195545 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA groups vs Control group
Number of subjects: 50
Study 7849875 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal marijuana exposure
Number of subjects: 18
Study 7849875 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 2183942 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg daily during RT)
Number of subjects: 89
Study 2183942 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg daily after RT)
Number of subjects: 89
Study 7426142 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 0.1 mg/kg intravenously followed by 320 mg in divided doses over 27 hours orally
Number of subjects: 62
Study 7426142 — intervention group
Group type: COMPARATOR
Intervention: Control group (29 patients)
Number of subjects: 62
Study 31156210 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep posture recording protocol using infrared cameras under various light and bed cover situations.
Number of subjects: 20
Study 29245871 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency-entangled state
Number of subjects: 0
Study 29245871 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichromatic path‐entangled state
Number of subjects: 0
Study 25886200 — intervention group
Group type: EXPERIMENTAL
Intervention: Welfare-to-work schemes combined with alcohol treatment
Number of subjects: 0
Study 25886200 — intervention group
Group type: COMPARATOR
Intervention: Welfare-to-work schemes alone
Number of subjects: 0
Study 23507858 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoselective vaporization of the prostate (PVP) with GreenLight HPS laser
Number of subjects: 200
Study 23507858 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 200
Study 21838823 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 30
Study 21838823 — intervention group
Group type: COMPARATOR
Intervention: Tracheal Tube (TT)
Number of subjects: 30
Study 19628959 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 65
Study 19628959 — intervention group
Group type: COMPARATOR
Intervention: Rogerian supportive therapy (RST)
Number of subjects: 65
Study 18614890 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise group (n = 15) participated in a 6-week, twice-weekly indoor exercise program (45 minutes of gymnastics with music and 15 minutes of progressive muscle relaxation)
Number of subjects: 30
Study 18614890 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise group
Number of subjects: 30
Study 18614890 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard medical care)
Number of subjects: 30
Study 15468140 — intervention group
Group type: EXPERIMENTAL
Intervention: Scyllo-inositol measurement in older subjects
Number of subjects: 24
Study 15468140 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol measurement in older subjects
Number of subjects: 24
Study 15468140 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest studies on scyllo-inositol
Number of subjects: 24
Study 15468140 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest studies on N-acetyl aspartate
Number of subjects: 24
Study 15468140 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between scyllo-inositol and myo-inositol levels
Number of subjects: 24
Study 11867375 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (3%-6% end tidal) with nitrous oxide 70% in oxygen
Number of subjects: 90
Study 11867375 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (0.7%-1.2% end tidal) with nitrous oxide 70% in oxygen
Number of subjects: 90
Study 11867375 — intervention group
Group type: COMPARATOR
Intervention: Propofol (75-150 microg kg(‐1) min(‐1) IV) with nitrous oxide 70% in oxygen
Number of subjects: 90
Study 10448260 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyl‐L‐glutamine supplementation
Number of subjects: 24
Study 10448260 — intervention group
Group type: COMPARATOR
Intervention: No glutamine supplementation (control)
Number of subjects: 24
Study 7603726 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular adaptation exercises
Number of subjects: 0
Study 7603726 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 2182891 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 23
Study 2182891 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation without therapy
Number of subjects: 23
Study 2182891 — intervention group
Group type: EXPERIMENTAL
Intervention: High expression of Ki-67, absence of CD9 and CD10, and blastic morphology
Number of subjects: 23
Study 2182891 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver involvement documented by biopsy
Number of subjects: 23
Study 2182891 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete responses lasting longer than 2 years
Number of subjects: 23
Study 7010382 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 23
Study 7010382 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (25 mg)
Number of subjects: 23
Study 7010382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 29112827 — intervention group
Group type: EXPERIMENTAL
Intervention: Average grams per cannabis administration
Number of subjects: 300
Study 27236654 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased LV threshold group
Number of subjects: 200
Study 27236654 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP increase
Number of subjects: 200
Study 27236654 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25 (OH)2 vitamin D decrease
Number of subjects: 200
Study 25056602 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (60 gray in 27 fractions)
Number of subjects: 117
Study 25056602 — intervention group
Group type: COMPARATOR
Intervention: Group B (68 gray in 34 fractions)
Number of subjects: 117
Study 21617973 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (Laser Smile™, Biolase®, San Clemente, USA) applied to the wound after surgery with 5 J/cm² energy density, 810 nm wavelength, and 0.5 W output power.
Number of subjects: 20
Study 21617973 — intervention group
Group type: COMPARATOR
Intervention: Control side (placebo) where a handpiece was applied but the laser was not activated.
Number of subjects: 20
Study 20370946 — intervention group
Group type: EXPERIMENTAL
Intervention: Test chocolate with maltitol (MTL)
Number of subjects: 40
Study 20370946 — intervention group
Group type: EXPERIMENTAL
Intervention: Test chocolate with MTL and polydextrose (PDX)
Number of subjects: 40
Study 20370946 — intervention group
Group type: EXPERIMENTAL
Intervention: Test chocolate with MTL and PDX
Number of subjects: 40
Study 18564999 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% liposomal lidocaine cream
Number of subjects: 18
Study 18564999 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 18
Study 16602203 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa)
Number of subjects: 0
Study 12888150 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0
Study 12888150 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 0
Study 12888150 — intervention group
Group type: COMPARATOR
Intervention: Untreated subjects with combined hyperlipidemia
Number of subjects: 0
Study 10084567 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg isoflavones from red clover
Number of subjects: 17
Study 10084567 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg isoflavones from red clover
Number of subjects: 17
Study 10084567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 7795355 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated pediatric odorant identification task (sniffing and identifying five odorants: baby powder, bubble gum, candy cane, licorice, peach)
Number of subjects: 825
Study 7795355 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated pediatric odorant identification task
Number of subjects: 825
Study 7795355 — intervention group
Group type: COMPARATOR
Intervention: Adult subjects with olfactory dysfunction
Number of subjects: 825
Study 1881295 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnomedicine (specific intervention details not provided)
Number of subjects: 0
Study 1881295 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational studies (case series)
Number of subjects: 0
Study 6776833 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent positive pressure breathing
Number of subjects: 17
Study 6776833 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 17
Study 31338563 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D, calcium and leucine-enriched whey protein drink (2/day)
Number of subjects: 380
Study 28168201 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week group-based lifestyle intervention program (n = 34)
Number of subjects: 70
Study 28168201 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard print material on diabetes prevention (n = 36)
Number of subjects: 70
Study 25466315 — intervention group
Group type: EXPERIMENTAL
Intervention: Humalog insulin (Hlog)
Number of subjects: 28
Study 23354552 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral palonosetron 0.25 mg
Number of subjects: 651
Study 23354552 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral palonosetron 0.50 mg
Number of subjects: 651
Study 23354552 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral palonosetron 0.75 mg
Number of subjects: 651
Study 23354552 — intervention group
Group type: EXPERIMENTAL
Intervention: IV palonosetron 0.25 mg
Number of subjects: 651
Study 23354552 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg IV
Number of subjects: 651
Study 23354552 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 651
Study 21034692 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (up to 2,500 mg/d flexibly dosed)
Number of subjects: 42
Study 21034692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 21034692 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 42
Study 19026570 — intervention group
Group type: EXPERIMENTAL
Intervention: Disc A (auditory information during anesthesia)
Number of subjects: 38
Study 19026570 — intervention group
Group type: EXPERIMENTAL
Intervention: Disc B (auditory information during anesthesia)
Number of subjects: 38
Study 19026570 — intervention group
Group type: COMPARATOR
Intervention: No auditory information (not heard during anesthesia) for Disc A
Number of subjects: 38
Study 19026570 — intervention group
Group type: COMPARATOR
Intervention: No auditory information (not heard during anesthesia) for Disc B
Number of subjects: 38
Study 17085269 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention directed toward both the patient and family caregivers
Number of subjects: 0
Study 17085269 — intervention group
Group type: COMPARATOR
Intervention: Conventional care alone
Number of subjects: 0
Study 14979621 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin as add-on therapy
Number of subjects: 561
Study 11337538 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg oral amphetamine
Number of subjects: 22
Study 11337538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9398701 — intervention group
Group type: EXPERIMENTAL
Intervention: GH and LH‐releasing hormone (LHRH) analog
Number of subjects: 14
Study 9398701 — intervention group
Group type: COMPARATOR
Intervention: GH and placebo
Number of subjects: 14
Study 7956639 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (NCT) plus deflazacort (DFL) for 3 months (25 mg.kg-1.day-1 for NCT, 0.6 mg.kg-1.day-1 for DFL in the first month, 0.3 mg.kg-1.day-1 for DFL in the other 2 months)
Number of subjects: 36
Study 7956639 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (NCT) plus deflazacort (DFL)
Number of subjects: 36
Study 7956639 — intervention group
Group type: COMPARATOR
Intervention: Nicotinamide (NCT) plus placebo
Number of subjects: 36
Study 3316240 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime administered 10 minutes before tourniquet inflation
Number of subjects: 0
Study 3316240 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime administered at various intervals before tourniquet inflation
Number of subjects: 0
Study 31657454 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab + short-term prednisone
Number of subjects: 0
Study 31657454 — intervention group
Group type: COMPARATOR
Intervention: Standard corticosteroid regimen (prednisone alone)
Number of subjects: 0
Study 30784669 — intervention group
Group type: EXPERIMENTAL
Intervention: Full post-PCI bivalirudin infusion (1.75 mg/kg/h for ≤4 h)
Number of subjects: 3610
Study 30784669 — intervention group
Group type: COMPARATOR
Intervention: Low post-PCI bivalirudin infusion (0.25 mg/kg/h for ≤6 h)
Number of subjects: 3610
Study 30784669 — intervention group
Group type: COMPARATOR
Intervention: No post-PCI bivalirudin infusion or heparin
Number of subjects: 3610
Study 28642308 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score containing age, smoking status, dyspnoea, prescriptions of salbutamol and prescriptions of antibiotics
Number of subjects: 2398
Study 28642308 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut-point of ≥7.5% predicted risk
Number of subjects: 2398
Study 25197733 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocobar ice cream with probiotics
Number of subjects: 30
Study 25197733 — intervention group
Group type: COMPARATOR
Intervention: Chocobar ice cream without probiotics
Number of subjects: 30
Study 23551727 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (5-40 mg/d)
Number of subjects: 537
Study 23551727 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ; 12.5-25 mg/d)
Number of subjects: 537
Study 23551727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 537
Study 21528169 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of soft plain cheese (fortified with vitamin D3 and calcium)
Number of subjects: 29
Study 21528169 — intervention group
Group type: COMPARATOR
Intervention: Control period (6 weeks without soft plain cheese consumption)
Number of subjects: 29
Study 18037478 — intervention group
Group type: COMPARATOR
Intervention: CT/RT
Number of subjects: 109
Study 18037478 — intervention group
Group type: EXPERIMENTAL
Intervention: CT/RT+R‐HUEPO
Number of subjects: 109
Study 17060297 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation
Number of subjects: 0